Ultragenyx Pharmaceutical, Inc. Forecast, price target & analysts
Ultragenyx Pharmaceutical, Inc. Target price 2025 - Analyst rating & recommendation
Ultragenyx Pharmaceutical, Inc. Classifications & Recommendation:
Ultragenyx Pharmaceutical, Inc. Price Target
| Target Price | $92.70 |
| Price | $35.37 |
| Potential |
162.09%
register free of charge
|
| Number of Estimates | 20 |
|
20 Analysts have issued a price target Ultragenyx Pharmaceutical, Inc. 2026 .
The average Ultragenyx Pharmaceutical, Inc. target price is $92.70.
This is
162.09%
register free of charge
$140.00
295.82%
register free of charge
$47.00
32.88%
register free of charge
|
|
| A rating was issued by 20 analysts: 19 Analysts recommend Ultragenyx Pharmaceutical, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Ultragenyx Pharmaceutical, Inc. stock has an average upside potential 2026 of
162.09%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 560.23 | 655.64 |
| 29.01% | 17.03% | |
| EBITDA Margin | -89.33% | -62.55% |
| 28.59% | 29.98% | |
| Net Margin | -103.75% | -72.47% |
| 40.90% | 30.15% |
18 Analysts have issued a sales forecast Ultragenyx Pharmaceutical, Inc. 2025 . The average Ultragenyx Pharmaceutical, Inc. sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Ultragenyx Pharmaceutical, Inc. EBITDA forecast 2025. The average Ultragenyx Pharmaceutical, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
20 Ultragenyx Pharmaceutical, Inc. Analysts have issued a net profit forecast 2025. The average Ultragenyx Pharmaceutical, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -6.29 | -5.14 |
| 23.76% | 18.28% | |
| P/E | negative | |
| EV/Sales | 5.45 |
20 Analysts have issued a Ultragenyx Pharmaceutical, Inc. forecast for earnings per share. The average Ultragenyx Pharmaceutical, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Ultragenyx Pharmaceutical, Inc....
Current Ultragenyx Pharmaceutical, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| JP Morgan |
Locked
➜
Locked
|
Locked | Mar 27 2025 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Mar 17 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Feb 26 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 18 2025 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Feb 18 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 14 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Jan 22 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
JP Morgan:
Locked
➜
Locked
|
Mar 27 2025 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Mar 17 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Feb 26 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 18 2025 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Feb 18 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 14 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Jan 22 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
